Trade Summary

6 days ago, Savitz Ryan, serving as EVP, CFO & CBO at Dianthus Therapeutics, Inc. /DE/ (DNTH), sold 31,249 shares at $101.03 per share, for a total transaction value of $3,157,150.86.

This sale represents a 100.00% decrease in Savitz Ryan's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, July 9, 2026 and publicly disclosed via SEC Form 4 filing on Monday, July 13, 2026 at 5:00 PM ET, 4 days after the trade was made.

Dianthus Therapeutics, Inc. /DE/ operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.